The IHAT Institute and Yale School of Medicine Present Research Findings at the Eastern Psychological Association Conference in NYC
- 0 Comments
By Sarah Allen Benton, MS, LMHC, LPC, AADC
The In-Home Addiction Treatment (IHAT) Institute has been collaborating with the Yale School of Medicine in conducting research about the Speranza Therapeutics FDA-cleared Percutaneous New Field Stimulator (PNFS) device. This device is designed to reduce opioid withdrawal symptoms through the application to the branches of several cranial and occipital nerves that modulate areas of the brain that involve fear and pain. The benefit is that it can help patients to decrease discomfort through noninvasive or medical interventions by targeting the symptoms directly. Once the device is applied to the client’s ear, the therapy begins and continues for up to 120 hours and treatment is determined by the patient’s reports of their Clinical Opiate Withdrawal Scale (COWS) feedback.
On March 4, 2022 The IHAT Institute and Yale School of Medicine presented their research poster at the Eastern Psychological Association conference in NYC. The retroactive case series was called “Percutaneous Electrical Nerve Field Stimulation to Reduce Clinical Opiate Withdrawal: A Case Series”. The results indicated a significant reduction in the client’s withdrawal symptoms to moderate by day 1 and mild by day 2. This reduction in symptoms allowed clients an opportunity to receive other treatment for their opioid use disorder.
The advantage of this type of detox option is that it can encourage clients who may otherwise be avoiding the discomfort of the typical detoxification process or not wanting to receive all of the traditional detoxification medications. It is also safe and able to be administered by a nurse.
With over 100,000 opioid-related overdose deaths in 2020, the PENF device is the type of innovation that could help to change the opioid use disorder treatment landscape during this crucial time.
The IHAT Institute is involved in other research projects, including with the Soberlink remote breathalyzer device and we will be releasing the results as soon as they are available.